$CLYM Cashflow Statement | Understand Stock

$CLYM

$9.57 +$0.76 (8.63%) Close

$CLYM Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Statements of Cash Flows

In millions of USD, except per-share amounts

	FY2025 12 months to Dec 31, 2025	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021
Cash flows from operating activities:
Net loss
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation expense
Right-of-use asset impairment
Non-cash operating lease expense
Change in fair value of redeemable convertible preferred stock tranche liability
Accretion of discounts on marketable securities, net
Foreign currency gain from remeasurement
Depreciation and amortization expense
In-process research and development, related party
Unrealized foreign currency transaction (gain) loss

Changes in operating assets and liabilities:
Prepaid expenses and other current assets
Long term assets
Long-term assets
Other long-term assets
Accounts payable
Accounts payable and accrued liabilities, related party
Accrued expenses and other liabilities
Accrued expenses and other current liabilities
Operating lease liabilities
Long-term liabilities
Net cash used in operating activities
Cash flows from investing activities:
Cash paid in connection with asset acquisition, net of cash acquired
Purchases of property and equipment
Purchase of marketable securities
Maturities of marketable securities
Issuance of promissory loan in connection with asset acquisition
Cash paid in connection with asset acquisition, net of cash received
Net cash provided by (used in) investing activities
Cash flows from financing activities:
Proceeds from initial public offering, net issuance costs
Proceeds from issuance of redeemable convertible preferred stock and related tranche rights, net of issuance costs
Proceeds from exercise of stock options
Pre-funded warrant issuance costs
Proceeds from issuance of common stock in private placement, net of issuance costs
Net cash provided by (used in) financing activities

Effect of exchange rate changes on cash and cash equivalents
Net change in cash and cash equivalents
Cash and cash equivalents at beginning of period
Cash and cash equivalents at end of period
Conversion of redeemable convertible preferred stock to common stock
Cash paid for leases included in operating cash outflows
Supplemental disclosure of non-cash investing and financing activities:
Issuance of common stock in exchange for in-process research and development
Settlement of promissory loan in connection with asset acquisition

Comments